根据诊断年份、分期、年龄和组织学类型评估子宫内膜癌 (EC) 的发病率和生存结果趋势。1999 年至 2018 年间诊断出原发性 EC 并随访至 2019 年的女性接受了韩国中央癌症登记处使用国际疾病分类第十版修订版确定。根据年龄、分期、组织学和诊断年份估计发病率的年龄标准化率 (ASR)、年度百分比变化 (APC) 和生存率。EC 的 ASR 从 1999 年的每 100,000 人 2.38 增加到每 100,000 人 7.29 2018 年所有组织学类型（子宫内膜样细胞、浆液细胞和透明细胞的 APC 分别为 9.82、15.97 和 7.73，p<0.001）。基于组织学的 5 年生存率存在显着差异（子宫内膜样细胞、浆液性细胞和透明细胞分别为 90.9%、55.0% 和 68.5%，p<0.001）、分期（93.4%、77.0% 和 31.0）分别为局部、区域和远处的百分比，p<0.001）和年龄（<50 岁为 93.0%，≥50 岁为 80.6%，p<0.001）。 2000年至2018年诊断组的5年生存率（85.9%）显着优于1999-2008年组（83.3%）（p<0.001）。仅在子宫内膜样癌中观察到这种趋势 (p<0.001)。所有 3 种亚型的 EC 发生率均增加。子宫内膜样组织学患者的生存率在过去二十年有所改善，但浆液性或透明细胞组织学患者的生存率保持不变。需要制定医疗保健策略来预防高危人群发生 EC 并对高危组织学应用有效的治疗方法。© 2024。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

To evaluate trends in the incidence and survival outcomes of endometrial cancer (EC) based on the year of diagnosis, stage, age, and histologic types.Women with primary EC diagnosed between 1999 and 2018, and who were followed up with until 2019, were identified from the Korea Central Cancer Registry using the International Classification of Diseases, 10th revision. The age-standardized rates (ASRs) of incidence, annual percent changes (APCs), and survival were estimated according to age, stage, histology, and year of diagnosis.The ASR for EC increased from 2.38 per 100,000 in 1999 to 7.29 per 100,000 in 2018 across all histologic types (APCs of 9.82, 15.97, and 7.73 for endometrioid, serous, and clear cell, respectively, p<0.001). There were significant differences in the 5-year survival rates based on histology (90.9%, 55.0%, and 68.5% for endometrioid, serous, and clear cell, respectively, p<0.001), stage (93.4%, 77.0%, and 31.0% for localized, regional, and distant, respectively, p<0.001), and age (93.0% for <50 years and 80.6% for ≥50 years, p<0.001). The 5-year survival was significantly better in the group diagnosed between 2000 and 2018 (85.9%) than that in the 1999-2008 group (83.3%) (p<0.001). This trend was only observed for endometrioid cancer (p<0.001).The incidence of EC increased across the all 3 subtypes. Survival of patients with endometrioid histology improved over the past two decades, but remained static for serous or clear cell histology. Healthcare strategies to prevent EC incidence in at-risk populations and apply effective treatments for high-risk histology are needed.© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.